Description: In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.

Description: Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.

Description: Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Description: BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clinical readouts, and discuss how it plans to deploy its cash resources while continuing to fund late-sta

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma

Description: Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing shift toward higher-value “affordable medicines” and specialty products, while highlighting near-term growth drivers across complex generics, biosimilars, and branded neurol

Description: Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.

Description: Pfizer CEO Bourla anticipates that the obesity market will “grow very fast” and reach $150bn by 2030.

Description: Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Description: AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.

Description: Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Bipolar Disorder: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a

Description: Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]

Description: ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.

Description: PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.

Description: We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]

Description: Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...

Description: AbbVie has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs. The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development. AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.

Description: As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc. (PFE), an iconic American blue chip that has climbed its own crowded wall of worry on top of the broader healthcare exodus, advises Tom Hayes, editor of HedgeFundTips.

Description: Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat

Description: Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

Description: SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ​Viagra in 1998, CEO Albert Bourla said on Monday. Bourla said that even when the drugmaker was ‌negotiating its purchase of weight-loss drugmaker Metsera, initially announced in September 2025, Pfizer did not expect the cash-pay market for obesity drugs ‌currently dominated by Eli Lilly and Co and Novo Nordisk to get s

Description: The National Retail Federation (NRF) is hosting its Retail's Big Show conference in New York City this week. Attending the event, Yahoo Finance Senior Reporter Brooke DiPalma sat down with KPMG US consumer & retail sector leader Duleep Rodrigo and PwC partner and US consumer markets industry leader Alison Furman to hear how retailers will be employing AI applications and how companies are expected to adjust to the adoption of GLP-1 weight-loss drugs and more active lifestyles by consumers. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend.

Description: Find insight on Pfizer, Johnson & Johnson and more in the latest Market Talks covering the health care sector.

Description: Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7, UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizer’s revenue outlook, with roughly $15 billion to $20 billion tied to major drugs expected […]

Description: Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.

Description: Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value

Description: Contract value passes $1.1 billion milestone

Description: Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.

Description: Monday is the first day of J.P. Morgan’s annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year. There is ample precedent: Last year, Johnson & Johnson announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering. The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.

Description: Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.

Description: The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based therapies. Key players like Pfizer and emerging biotechs are driving advancements, creating growth prospects in this evolving sector.Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The "CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026" report has been

Description: AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.

Description: CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc

Description: NEW YORK, January 10, 2026--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem

Description: Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P. Morgan Healthcare Conference on January 9, 2026. At the same time, a downgrade from Wolfe Research on valuation and competitive grounds has sharpened investor focus on the durability and breadth of Madrigal’s MASH franchise. We’ll now examine how Wolfe Research’s valuation downgrade, alongside...

Description: There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading strategies.

Description: NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: It could be another tough year for the once-soaring drugmaker.

Description: BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure

Description: Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical compa

Description: The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.

Description: US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...

Description: In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with Cartography Biosciences will use its ATLAS and SUMMIT platforms to discover tumor-selective antigens that Pfizer can advance into oncology programs. Together, these alliances highlight Pfizer’s push to use advanced AI and precision oncology tools to improve its internal pipeline productivity at a time...

Description: NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U. pricing last year under pressure from President Donald Trump.

Description: Boltz partnership targets faster early decisions

Description: Collaboration aims to accelerate preclinical research with biomolecular AI models.

Description: These high-yielding dividend stocks pay 5% or more, and make for safe income investments to hold on to.

Description: Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.

Description: Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, Astellas Pharma and Pfizer Inc. (NYSE:PFE) announced positive topline results from the Phase 3 EV-304 clinical trial (also called KEYNOTE-B15). This study showed that the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) improves […]

Description: Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced a strategic collaboration to empower scientists across the company with state-of-the-art biomolecular AI foundation models and generative workflows for small-molecule and biologics design.

Description: These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors now.

Description: The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration. After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.

Description: SAN FRANCISCO, January 08, 2026--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

Description: Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March. The dividend...

Description: This big pharma stock still faces significant challenges in the new year.

Description: The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Description: Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

Description: Pfizer and BioNTech previously announced that their jointly developed COVID-19 vaccine showed over 90% effectiveness in preventing infection based on initial trial data, although scientists highlighted unanswered questions about long-term protection and impact on severe disease. This early efficacy signal positioned BioNTech’s mRNA platform at the center of the global pandemic response, while simultaneously underscoring the scientific and regulatory uncertainties that still surround...

Description: AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.

Description: (Updates with BioNTech response in the sixth paragraph.) Bayer's Monsanto unit filed patent infri

Description: Bayer's Monsanto unit filed patent infringement lawsuits Tuesday against COVID-19 vaccine makers Pfi

Description: If you are wondering whether Pfizer's current share price offers value for what you are getting, this article breaks down the numbers so you can assess that for yourself. Pfizer's share price last closed at US$25.17, with returns of 0.7% over 7 days, a 3.3% decline over 30 days, and a negative return over 1 year and 3 years of 37.1%. Recent headlines around Pfizer have focused on shifting expectations for its wider pharmaceutical portfolio and how investors weigh long term prospects beyond...

Description: The iShares Select Dividend ETF (NYSEARCA:DVY) has become a cornerstone holding for income-focused retirees seeking reliable dividend income. With a yield of 3.61%, the fund delivers nearly triple the S&P 500’s yield while maintaining exposure to 100 dividend-paying U.S. equities. The ETF’s appeal extends beyond yield alone: DVY appreciated 13% over the past year, delivering ... iShares Select Dividend Fund Has A Surprisingly High Yield For Retirees

Description: Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: SOUTH SAN FRANCISCO, Calif., January 06, 2026--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identif

Description: Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

Description: Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs, even as President Donald Trump has reached agreements with 14 pharmaceutical companies to lower prices on […]

Description: DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Description: Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its past three-month return at a 4.1% decline, sharpening focus on its current valuation. See our latest analysis for Pfizer. At a share price of US$25.18, Pfizer’s 7 day and 1 day share price returns in positive territory contrast with its weaker 30 and 90 day share price returns and its 3 year total shareholder return of 38.1% decline, suggesting momentum has been fading...

Description: Investors seem to be underestimating this company's foreseeable future.

Description: NEW YORK, January 05, 2026--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST.

Description: Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Description: Both Ford and Pfizer have very attractive dividend yields.

Description: Income investors probably don't need to worry about a dividend cut from Pfizer in the new year.

Description: The latest trading day saw Pfizer (PFE) settling at $25.18, representing a +1.12% change from its previous close.

Description: The company's prospects are stronger than its stock-market performance in 2025 suggests.

Description: Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on December 17. The pharmaceutical company anticipates adjusted profit to be between $2.80 and $3 per share in the upcoming year. In […]

Description: Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.

Description: US equity markets are poised to get a boost from strong corporate earnings this year as spending con

Description: It might not pay off immediately, but it could, eventually.

Description: The money could flow in with these great dividend stocks.

Description: Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.

Description: Health care stocks declined late Wednesday afternoon with the NYSE Health Care Index dropping 0.5% a

Description: <body><p>STORY: :: Bristol Myers Squibb </p><p>:: File</p><p>Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including vaccines and blockbuster cancer treatment Ibrance.</p><p>:: CVS</p><p>That's according to data provided exclusively to Reuters by healthcare research firm 3 Axis Advisors.</p><p>The hikes come even as the Trump administration is pressuring drugmakers for cuts.</p><p>:: CVS</p><p>The number of price increases is up from the same point last year while the median price hike of four percent is in line with 2025.</p><p>The increases do not reflect any rebates to pharmacy benefit managers and other discounts.</p><p>:: Boehringer Ingelheim</p><p>Drugmakers also plan to cut the list prices on around nine drugs including diabetes treatment Jardiance, which is dropping 40%.</p><p>It is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026.</p><p>:: Pfizer</p><p>A health policy researcher tells Reuters these deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.</p><p>:: CVS</p><p>U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations.</p><p>Pfizer announced the most list price hikes, on around 80 different drugs including cancer drug Ibrance, and its COVID vaccine, which is going up 15%.</p><p>:: Pfizer</p><p>:: File</p><p>Pfizer said in a statement it had adjusted the average list price of its innovative medicines and vaccines for 2026 below the overall rate of inflation.</p><p>:: CVS</p><p>More price hikes and cuts can be expected in early January, which is historically the biggest month for drugmakers to raise prices.</p></body>

Description: Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index and the State Stree

Description: Drugmakers Brace for January Price Changes

Description: List prices to rise an average of 4% despite federal pressure to curb costs.

Description: It's always a great time to buy quality dividend stocks.

Description: Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.

Description: Pfizer (PFE), Sanofi (SNY), Novartis (NVS), and GSK (GSK) are among the drug makers planning price i

Description: Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 16, Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy, starting in 2026. The company pointed to lower sales of its COVID vaccine and treatment, price cuts promised to the US government, and […]

Description: AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

Description: The stock has been on the rebound for several months, but can it keep the momentum going?

Description: In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Description: Jim Cramer has built a strong reputation in the industry. He’s the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs. When it comes to dividend stocks, he thinks there are many stocks with a high yield, but as yields soar, it can become dangerous since ... Jim Cramer Names His Favorite Dividend Stocks

Description: These income stocks look like smart buys right now.

Description: The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Description: High dividend yields don't matter if they aren't supported by quality businesses.

Description: Bristol Myers Squibb could become the pharmaceutical industry’s turnaround story for 2026. Shares are off 9% in 2025 after a series of drug pipeline disappointments, while major patent expirations, like one for cancer drug Revlimid, could cause earnings to fall 5% in 2026 and another 5% in 2027. At the current price, investors are paying little for Bristol Myers’ pipeline, led by Cobenfy, a schizophrenia drug being tested as a treatment for psychosis among Alzheimer’s patients, and Milvexian, a treatment of atrial fibrillation and strokes.

Description: Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.

Description: CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.

Description: Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.

Description: As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Description: Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer’s 2026 guidance revealed a steeper erosion of its COVID-19 franchise than […]

Description: If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

Description: Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.

Description: Earlier in December 2025, Pfizer disclosed that a participant in its long-term Hympavzi hemophilia trial died following serious cerebrovascular complications, while also tightening revenue guidance for 2025 and issuing an initial outlook for 2026 that reflects ongoing patent and pricing headwinds. At the same time, Pfizer is leaning heavily on its oncology and immunology pipeline, including positive Phase 3 data for TUKYSA and PADCEV combinations and new AI-enabled and TCR-focused...

Description: Continued revenue growth and commercial projects fuel Telescope's successful intelligent automation and advanced chemical manufacturing portfolioVancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, reports financial results for the fiscal year ended August 31, 2025. The...

Description: In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day.

Description: Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally h

Description: BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.

Description: Hemophilia Drug Hympavzi Under Scrutiny as Adverse Event Sparks Market Jitters

Description: XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.

Description: Vaxcyte stock kept its place as one of Mizuho’s top picks entering 2026, with the firm reiterating an Outperform rating and a $163 price target in a research note. Vaxcyte is advancing to phase 3 trials for its shot, VAX-31, in adults and phase 2 trials for infants. It could eventually be a leader in an $8 billion market, Mizuho argued.

Description: Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded Repertoire® Immune Medicines will identify and optimize TCR bispecifics for metastatic prostate cancer.

Description: In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event-free and overall survival, with higher pathologic complete response rates and a safety profile consistent with prior data. The strength of these pivotal results could meaningfully reinforce PADCEV’s role within Astellas’ oncology portfolio, particularly in earlier-stage bladder cancer where...

Description: Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.

Description: Astellas Pharma (TSE:4503) just cleared an important milestone with Pfizer, as their PADCEV plus Keytruda combo hit primary and key secondary endpoints in a Phase 3 bladder cancer trial, sharpening the stock's long term growth story. See our latest analysis for Astellas Pharma. The market has been warming to that oncology story, with Astellas Pharma’s share price delivering a strong year to date return of 37.52 percent and a 1 year total shareholder return of 42.97 percent, underpinned by a...

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer shed light on. During the lightning round, a caller sought Cramer’s opinion on the stock, and he said: “Okay, Pfizer, really good yield, not a lot of momentum. Didn’t like the update yesterday. I’m going to say just weak hold.” Pfizer Inc. (NYSE:PFE) creates and […]

Description: If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite a tough few years, the stock has inched up about 2.5% over the last year, even though it is still down roughly 5.3% year to date and more than 40% over three years, a mix that often signals shifting expectations around risk and recovery potential. Recent attention has focused on how Pfizer is...

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.

Description: Today, the New York State Emerging Technology Advisory Board (ETAB) released its final report of recommendations to Governor Kathy Hochul. Led by co-chairs Deborah W. Brooks, CEO and co-founder of The Michael J. Fox Foundation for Parkinson's Research (MJFF), and Andrew Baum, chief strategy and innovation officer of Pfizer, the ETAB's recommendations aim to bolster New York's position as a global biotechnology hub and as a place where innovation fuels healthier, stronger communities.

Description: The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and consume food.

Description: This year has been one to forget for these pharmaceutical giants.

Description: The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.

Description: Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Description: Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.

Description: We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The […]

Description: We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]

Description: Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

Description: Your decision on whether to invest now depends to some extent on your investment strategy.

Description: The stocks listed here trade at forward earnings multiples of less than 18.

Description: These two stocks have been going in opposite directions over the past few years.

Description: J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Description: NEW YORK, December 18, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning.

Description: We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Pfizer Inc tops our list for being one of the most undervalued pharmaceutical stocks. On Friday, December 12, 2025, The Fly reported that Morgan Stanley maintained its Hold (Equal‑Weight) rating on PFE., while lowering the price target to $28 from […]

Description: Pfizer's shares look attractive to investors willing to show patience.

Description: CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.

Description: PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.

Description: Companies in The News Are: PFE,KHC,F,PYPL

Description: It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.

Description: The main US stock measures were tracking in the green in Wednesday's premarket activity as traders d

Description: Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) vers

Description: COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm

Description: Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.

Description: In the latest trading session, Pfizer (PFE) closed at $25.57, marking a -3.27% move from the previous day.

Description: The Dow Jones Industrial Average and the S&P 500 fell for a third straight session on Tuesday as tra

Description: Stock Market Today: The Dow Jones index dropped Tuesday after a surprise November jobs report. Palantir and Tesla traded lower.

Description: Monte Rosa Therapeutics surged Tuesday after the biotech said every patients in a prostate cancer study responded to its treatment.

Description: Pfizer stock tumbled Tuesday after the drugmaker missed Wall Street's earnings forecast following a suite of acquisitions.

Description: Stocks were mixed Tuesday as U.S. hiring in November was stronger than expected and the unemployment rate jumped to 4.6%. Ford was up 0.2%. The auto maker announced a pivot toward hybrids and away from electric cars.

Description: Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues while limiting shareholder payouts.The drugmaker expects a drop of $1.5 billion in 2026 revenues tied to lower Covid-19 sales and the decline of another $1.5 billion from products experiencing a loss of exclusivity.

Description: Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and

Description: Pfizer (PFE), Humana (HUM), and Kraft Heinz (KHC) are some of the trending tickers on Yahoo Finance's platform on Tuesday. Market Domination host Josh Lipton and Yahoo Finance Senior Reporter Brooke DiPalma examine the stories driving investor interest in the names. To watch more expert insights and analysis on the latest market action, check out more Market Domination.

Description: US benchmark equity indexes were lower intraday as traders parsed the latest economic data, includin

Description: Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the lucrative obesity market.

Description: Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.

Description: Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 sales fade and key drugs lose exclusivity, putting near term growth firmly under the microscope. See our latest analysis for Pfizer. Even with today’s dip on the 2026 guidance, Pfizer’s 90 day share price return of 10.59% suggests sentiment has been quietly improving, while the 1 year total shareholder return of 12.25% hints that long term confidence is slowly...

Description: All three major US stock indexes were pointing lower in late-morning trading on Tuesday, as investor

Description: Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday. “We will continue investing in vaccines because, as I said, this is an anomaly that will correct itself, I hope pretty soon,” Bourla said. Pfizer shares were down 4.9% Tuesday to $25.13 after the company issued 2026 guidance that came in slightly below expectations and said it expects a return to growth at the end of the decade.

Description: Pfizer Sees Revenue Decline, Shifts Focus to New Drugs

Description: Loss of exclusivity and lower pandemic-related demand weigh on outlook.

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Pfizer (PFE) expects flat sales growth in its 2026 forecast, Kraft Heinz (KHC) names former Kellanova (K) CEO Steve Cahillane as its next chief executive ahead of the food company's split, and PayPal (PYPL) filing for a US bank charter. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors

Description: BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.

Description: Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: DSMB Ends Comparator Arm; Trial Proceeds Exclusively With GEO-CM04S1 Following mRNA Vaccine's Failure to Meet Primary Endpoint Phase 2 Data Reinforce GEO-CM04S1 as an Important Next-generation Vaccine Candidate for the 40 Million U.S. and 400 Million...

Description: A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat

Description: IDEAYA Biosciences recently completed full enrollment of 435 patients in its registration-enabling Phase 2/3 OptimUM-02 trial testing oral PKC inhibitor darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, while also advancing IDE034 and IDE574 into early-stage clinical development. This milestone underscores IDEAYA’s push to convert promising early uveal melanoma data and multiple FDA designations for darovasertib into a potential accelerated...

Description: Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Description: It's time for investors to give up on the telemedicine leader.

Description: NEW YORK, December 12, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer.

Description: Keep your expectations in check.

Description: LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.

Description: Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

Description: Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.

Description: CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.

Description: The cuts follow a broader downgrading of the drug manufacturer’s Swiss operations.

Description: GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.

Description: ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.

Description: Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living with hemophilia A or B with inhibitors. The study included 48 adults and adolescents with severe hemophilia A or B. Patients […]

Description: IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free

Description: Amy Schulman is the second veteran of the pharmaceutical industry that Elevance has added to its board this year.

Description: Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer expectations for revenue growth are set against a more supportive backdrop for U.S. drug pricing and renewed interest in large cap biopharma, helping to stabilize the valuation case. As these shifts play out alongside evolving views on Pfizer’s pipeline and deal making, investors can follow the...

Description: The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index adding 1.6% and the

Description: Invesco High Dividend Low Volatility ETF (NYSEARCA:SPHD) generates its 4.71% yield – roughly three times the S&P 500’s current dividend – by holding a concentrated portfolio of 50 U.S. stocks selected for high dividend yields and low volatility. With $3.1 billion in assets and a reasonable 0.30% expense ratio, SPHD takes an equal-weight approach to ... This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)

Description: Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison […]

Description: NEW YORK, December 10, 2025--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amo

Description: Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.

Description: JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.

Description: What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to start your day.

Description: US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050

Description: Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.

Description: In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

Description: Recently, Pfizer Inc. announced an exclusive global collaboration and license agreement with YaoPharma to develop, manufacture and commercialize YP05002, an oral small-molecule GLP-1 receptor agonist currently in Phase 1 for chronic weight management, alongside new Phase 3 data showing HYMPAVZI improved bleeding outcomes for people with hemophilia A or B with inhibitors. The YaoPharma deal, which includes a US$150 million upfront payment and potential milestones of up to US$1.94 billion plus...

Description: Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.6% and th

Description: Pfizer (PFE) said Tuesday that it will develop Chinese drug manufacturer YaoPharma's weight loss the

Description: Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

Description: Agreement deepens company's push into fast-growing weight-loss market

Description: All three major US stock indexes were edging higher in late-morning trading on Tuesday after the Fed

Description: Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.

Description: This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

Description: Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece

Description: NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana

Description: A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.

Description: The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi

Description: By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful development and commercialization of onvansertib for first line treatment of patients with metastatic colorectal cancer (mCRC). Onvansertib is a Polo-Like kinase 1 (PLK1)

Description: Companies are rolling out direct-to-patient services, which are selling drugs for weight loss and other uses.

Description: NEW YORK, December 06, 2025--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no t

Description: Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID revenue collapse while Teva is accelerating through an innovation-led turnaround that has delivered 11 consecutive quarters of growth. One Declining, One Accelerating Pfizer posted Q3 revenue of ... Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue

Description: Wondering if Pfizer is quietly turning into a value opportunity, or if the market is still too skeptical, you are not alone. That is exactly what this breakdown will unpack. After a rough few years, Pfizer's share price has ticked up 1.1% over the last week and 5.8% over the past month, even though it is still down 2.2% year to date and 40.1% over three years, with a modest 8.5% gain over the last year. Recent sentiment has been shaped by Pfizer's shifting pipeline strategy and portfolio...

Description: These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.

Description: There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.

Description: Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Description: CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.

Description: Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.

Description: We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.27 as of December 1st. PFE’s trailing and forward P/E were 14.97 and 8.50 respectively according to Yahoo Finance. Pfizer Inc. (PFE) has emerged from the post-COVID period as a transformed […]

Description: Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: The report highlights opportunities in pharmaceutical outsourcing through emerging trends, new contracts, M&A activities, and investments in technology. It guides CMOs, pharmaceutical decision-makers, and investors in strategic planning and supplier management by providing insights into regulatory impacts and supply chain developments.Dublin, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, October 2025" report has been added to ResearchAndMarkets.com's offering.The

Description: In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

Description: Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases. ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announced the release of a new interview with strategic consultant Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response, Cramer said: “2026, yeah, there is. It’s got, they got a lot of irons in the fire. I think […]

Description: The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. In addition, the increasing prevalence and the launch of emerging therapies, such as inclacumab (Pfizer), etavopivat (Novo Nordisk), mitapivat (Agios Pharmaceuticals), osivelotor (Pfizer), and others, will also contribute to the growing market size during the forecast period.New York, USA, De

Description: Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.

Description: Pfizer (PFE) shares have shown some movement this week, drawing attention for investors evaluating the company’s current position and recent performance. The stock’s slight rebound over the past month is notable, particularly after a period of declines earlier this year. See our latest analysis for Pfizer. Pfizer’s share price has turned a corner after earlier weakness this year, with a modest 2.5% gain over the past month that points to emerging momentum. However, the long-term picture...

Description: The nanopharmaceuticals market presents opportunities in addressing chronic diseases through enhanced targeted therapies and bioavailability. Personalization in treatments, particularly in oncology, is a key trend. However, high R&D costs and regulatory hurdles pose challenges. Key players include Merck, Pfizer, and Novartis. Nanopharmaceuticals Market Nanopharmaceuticals Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Oppor

Description: Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.

Description: Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.

Description: Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Description: Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.

Description: Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam Pharmaceuticals.

Description: Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, and healthcare products. It is set to report its Q4 2025 earnings on Feb. 3. Wall Street analysts expect the company ...

Description: These healthcare leaders can make you money while you sleep.

Description: Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.

Description: Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become stricter.

Description: The move marks a victory for the Trump administration’s campaign to get other countries to pay more for drugs.

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the stock hit vaccine makers Moderna (MRNA), BioNTech (BNTX), and Novavax (NVAX) are taking on following a memo from the US Food and Drug Administration (FDA); casino operator Bally's (BALY) has won approval to run casinos in New York City; and Somnigroup International's (SGI) $1.6 billion offer to acquire Leggett & Platt (LEG). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Description: CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.

Description: Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

Description: Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official claimed the shots led to 10 children’s deaths and said the agency would tighten vaccine-approval standards. Shares of Moderna and Novavax, which depend heavily on Covid-19 vaccine sales for revenue, fell about 6% and 3.5%, respectively. Stock in Pfizer, whose Covid-19 vaccine sales are a smaller percentage of total company revenue, ticked higher.

Description: NEW YORK, December 01, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose of the call is to provide Pfizer’s full-year 2026 financial guidance.

Description: Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.

Description: PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT),

Description: Investing.com -- Shares in major COVID-19 vaccine makers fell on Monday after an internal U.S. Food and Drug Administration (FDA) memo reportedly suggested that vaccinations may have contributed to several child deaths linked to heart inflammation.

Description: While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Description: Retailers aren't the only ones with holiday sales; investors can also find high value for low prices in the stock market (^DJI, ^GSPC, ^IXIC). Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks in Translation podcast, explains where investors should look to find the best value stocks this holiday season. Catch more Stocks in Translation, with new episodes every Tuesday and Thursday. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.

Description: One drug developer could be on the cusp of AI-powered glory.

Description: If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.

Description: Strategy has made no secret of the fact that it would like to join the S&P 500 — but at least for now, a spot in this flagship index remains elusive.Earlier this week, the Bitcoin treasury company was snubbed again, with Sandisk joining the ranks of America’s most prestigious large-cap ...

Description: Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...

Description: Biotech stocks remain prevalent on the IBD 50 list of winning growth names. While many biotech names are extended, Stoke Therapeutics and Mirum Pharmaceuticals are both in or forming bases. Biotech stocks have made tremendous progress off April lows.

Description: JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.

Description: The Global Nasal Drug Delivery Market presents opportunities driven by increased patient preference for non-invasive methods, rising chronic respiratory conditions, and innovations in nose-to-brain drug delivery for CNS treatments. Key players like GlaxoSmithKline and Pfizer are optimizing formulations to overcome permeability challenges. Nasal Drug Delivery Market Nasal Drug Delivery Market Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The "Nasal Drug Delivery Market - Global Industry Size, Share,

Description: While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.

Description: Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]

Description: PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.

Description: NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.

Description: These top dividend stocks could intrigue a wide range of investors.

Description: Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.

Description: ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

Description: Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: The weight loss drug market may approach almost $100 billion by the end of the decade.

Description: Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)Results confirm benefits of a yearly vaccination prior to each Lyme season Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease va

Description: The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs. The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes. The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.

Description: Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.

Description: The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.

Description: J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Description: The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Description: This big pharma stock should be even more appealing to investors amid market turbulence.

Description: Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...

Description: As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

Description: Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.

Description: Among those chosen to help in his move to City Hall are former Goldman Sachs Group Inc. partner Margaret Anadu, developer Jed Walentas and Kathy Wylde, head of the Partnership for New York City. Wylde and Anadu will serve on the Committee on Economic Development & Workforce Development, and Walentas will join the Committee on Housing, according to a statement from Mamdani’s transition team on Monday.

Description: President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.

Description: Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.

Description: The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads

Description: LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.

Description: RVL Pharmaceuticals, Inc and its affiliates (together, "RVL") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.

Description: NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b

Description: UnitedHealth Group Incorporated (NYSE:UNH) is among the stocks Wall Street analysts are watching closely. On November 11, Wells Fargo analyst Stephen Baxter reaffirmed a Buy rating on UnitedHealth with a price target of $400. Earlier on November 3, a Barclays analyst had also maintained his Buy rating and a $386 price target. Analysts’ opinion on […]

Description: For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders.

Description: Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped just 0.1% in the last week, inched up 1.3% over the past month, but are still down 5.9% year to date despite a 4.7% return over the last twelve months. Recent headlines about Pfizer have focused on its latest product developments and major moves in the pharmaceutical sector, generating speculation...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Description: RAHWAY, N.J., November 21, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who a

Description: Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy

Description: Watch the Video I began the conversation with Lee by noting how rarely investors stop to consider how dramatically the upper ranks of the stock market have changed. When we looked back twenty five years, the list of dominant companies in the S&P 500 was almost unrecognizable compared with today. What the Top of the ... The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing

Description: Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: The drugmaker may not continue to lag the market for much longer.

Description: Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.

Description: Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...

Description: BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.

Description: Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.

Description: For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.

Description: When the AI bubble bursts, Altria will look like a pretty good investment again. It has paid out billions in dividends over the years, and that is unlikely to stop.

Description: The company's earnings fell by 21% last quarter.

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

Description: A day after the White House proclaimed that Saudi Arabia boosted its spring pledge to invest $600 billion in the US to a tidy $1 trillion during Crown Prince Mohammed bin Salman’s visit to Washington, DC, President Donald Trump said companies from both nations inked $270 billion in deals at a US-Saudi business forum. No timeline was given for Saudi Arabia’s $1 trillion in investments and, while the US-Saudi Investment Forum on Wednesday drew corporate royalty from Chevron, Tesla, Nvidia, Qualcomm, Cisco, General Dynamics, Pfizer and more, it wasn’t immediately clear which companies inked deals. Trump did say GE Aerospace will “deliver dozens of new engines” while a handful of other pacts, while short on financial details, highlighted some international bargaining.

Description: Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the

Description: Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a difference.

Description: Pfizer (PFE) CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see lower drug prices. Pfizer is among the companies that have made deals with the White House on pharmaceutical pricing. Make sure to watch Yahoo Finance's full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati

Description: The global bacterial vaginosis market is experiencing rapid growth, fueled by a rise in incidence due to lifestyle and hygiene changes. Increasing awareness is driving demand for innovative treatments, including probiotics and precision medicine. Investments from both the government and private sector, especially in women's health, are accelerating market growth. However, challenges such as side effects of current treatments persist. As research advances and emphasis on sustainable solutions int

Description: The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula

Description: Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.

Description: Saudi Crown Prince Mohammed bin Salman’s overtures to U.S. political and business leaders will continue Wednesday, but on somewhat friendlier terms. Bin Salman, the de facto ruler of Saudi Arabia, took questions from the press alongside President Donald Trump Tuesday. The event turned combative after Trump bristled at a reporter’s probing questions.

Description: Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.

Description: Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal

Description: Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Description: The market is hopping with interesting news.

Description: Pfizer (PFE) shares have shown resilience, with a modest uptick over the past week and month. Investors are keeping an eye on the stock’s performance as the company navigates market trends and changing sentiment. See our latest analysis for Pfizer. Despite a challenging year for many large-cap healthcare names, Pfizer's recent momentum hints at a shift in sentiment. While the share price is still down for the year to date, the one-year total shareholder return has turned positive. This...

Description: J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.

Description: PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.

Description: The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem

Description: The global hemophilia market is experiencing robust growth, fueled by advances in gene therapy and recombinant clotting factors. Increased awareness and healthcare investment worldwide are expanding access to innovative treatments such as extended half-life therapies and novel biologics, enhancing patient outcomes. The U.S. market drives this expansion, supported by a strong healthcare infrastructure and evolving regulatory landscape. However, high therapy costs and regulatory hurdles remain cha

Description: The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory health, and a rising demand for effective management solutions. Key drivers include the development of advanced drainage systems, anti-inflammatory drugs, and minimally invasive treatments like thoracentesis and pleurodesis. As awareness of pleural effusion's risks increases, early detection and intervention remain crucial. Despite ch

Description: The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio

Description: Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors and gene therapy, are revolutionizing patient outcomes through less frequent dosing and potential long-term solutions. Rising awareness and improved diagnostics hasten early detection, boosting demand. However, high treatment costs and regulatory hurdles present challenges. Key players like Alnylam

Description: The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary treatments like Hemgenix and Beqvez offer potential functional cures by reducing bleeding rates. Early detection using next-generation sequencing enhances patient management and personalized care. Despite challenges such as high costs and limited long-term safety data, leading companies like UniQure and Pfi

Description: Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting

Description: Eli Lilly might soon join them for a far different reason: the weight-loss bonanza. This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker Novo Nordisk That is why investors shouldn’t assume the rally stops at a trillion. Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.

Description: Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

Description: Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”

Description: Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.

Description: Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.

Description: By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13 th , 2025, press release and in its Form 10-Q filing. The reports were followed by a conference call, which discussed recent achievements, regulatory updates, trial

Description: Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.

Description: At Yahoo Finance Invest 2025, Albert Bourla and Ed Bastian shared the values that helped them lead companies through crisis.

Description: The company has been on an acquisition spree for years, and this one may be the most important yet.

Description: BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave of trading activity and market discussion. See our latest analysis for BioNTech. BioNTech’s share price has edged down nearly 2% this year, with momentum cooling further in recent months as investors weigh Pfizer’s exit and slowing Covid-19 vaccine revenues against a robust pivot back to oncology...

Description: Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer's investment outlook and what to watch going forward. Analyst Price Targets don't always capture the full story. Head over to our Company...

Description: Gain insight on bidding wars in the pharmaceuticals sector, Novo Nordisk and more in the latest Market Talks covering the health care sector.

Description: Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying significantly more than it had hoped.

Description: Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.

Description: The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.” “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said. Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.

Description: Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.

Description: Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

Description: Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

Description: Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...

Description: Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting. Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk Board of Dire

Description: Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index and the Health

Description: Pfizer CEO Albert Bourla says RFK Jr.'s appointment was not up to him, but he has found common ground with the vaccine skeptic.

Description: US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.

Description: Health and Human Services Secretary Robert F. Kennedy, Jr. has come under fire for his views on vaccines. In an interview with Yahoo Finance, Pfizer (PFE) CEO Albert Bourla says that Kennedy wouldn't have been his pick to lead HHS. Find out why in the video above. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: The sector is up almost 7% since the start of November, while the broader market is down more than 1%.

Description: Starboard’s Jeff Smith says activism isn’t about destruction — it’s about discipline, efficiency, and motivating complacent CEOs.

Description: Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.

Description: $508M share sale marks end of a Covid-era alliance--just as Pfizer doubles down on weight-loss moonshots

Description: Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss the future of medicine and pharmaceuticals, and what impact he believes artificial intelligence (AI) will have. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: All three major US stock indexes were down after midday trading Thursday, following President Donald

Description: Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major market.

Description: Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright. The company plans to enter the GLP-1 space by 2028 and aims to become a leader in the obesity market. Bourla also notes that the next big breakthrough in medicine could be aided by the use of artificial intelligence and discusses Pfizer's relationship with the White House. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to share that Pfizer will enter the obesity market by 2028 after paying $10B to acquire Metsera (MTSR). The drugmaker won out over rival Novo Nordisk (NVO) in its bid for the company. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: NEW YORK, November 13, 2025--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: If you love investing or want to love investing, Yahoo Finance's annual Invest event is here to help!

Description: Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.

Description: The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability metric.

Description: Turn health into wealth with these three high-yielding dividend stocks.

Description: Dr. Richard Pazdur is “likely the best possible person for the role,” says one analyst. A calmer course for the FDA could add fuel to the recent run-up in biotech stocks.

Description: We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed. Amgen Inc. (NASDAQ:AMGN) is a drug company that makes and sells medicines for a wide variety of ailments, such as arthritis and ulcers. Just like he […]

Description: We recently published 12 Latest Stocks on Jim Cramer’s Radar . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Jim Cramer has discussed pharma giant Pfizer Inc. (NYSE:PFE) several times recently. He has repeatedly commented on how the stock trades more like a bond rather than an equity due to its […]

Description: We recently published 12 Latest Stocks on Jim Cramer’s Radar . CoreWeave, Inc. (NASDAQ:CRWV) is one of the stocks Jim Cramer recently discussed. CoreWeave, Inc. (NASDAQ:CRWV) is a computing infrastructure firm that hosts GPUs and other hardware for AI software companies. Its inventory of NVIDIA GPUs has made the firm a key player in the […]

Description: Pfizer (PFE) managed to outbid competitor Novo Nordisk (NVO) to acquire Metsera (MTSR) in a deal valued at up to $10 billion. Pfizer stock is down by nearly 3% from this time a year ago. Robinhood (HOOD) Chief Investment Officer Stephanie Guild and Yahoo Finance senior reporters Brooke DiPalma and Ines Ferré discuss Pfizer's position in the healthcare space (XLV) and whether artificial intelligence could unlock new growth prospects for the pharmaceutical industry. Tune in on Thursday, November 13, for Yahoo Finance's interview with Pfizer CEO Albert Bourla at Yahoo Finance Invest. To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: The United States Dietary Supplements Market, projected to grow from US$ 54.24 billion in 2024 to US$ 103.56 billion by 2033, is driven by rising health awareness and demand for preventive healthcare, alongside growing fitness trends and an aging population. Busy lifestyles, online retail expansion, and innovation in supplement formulations further stimulate market growth. Popular for their role in enhancing immunity, fitness, and general health, dietary supplements include vitamins, minerals, a

Description: Value-driven plays abound in the top healthcare stocks.

Description: NEW YORK, November 12, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT.

Description: The biotech start-up's stock had been rising rapidly in 2025.

Description: Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating update from TD Cowen analyst Steve Scala on November 4, who maintained a Hold rating on the stock and set a $30 price target. Pfizer Inc. (NYSE:PFE) reported its fiscal Q3 2025 results the same […]

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the company’s acquisition of Metsera during the episode. He commented: “There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be bigger than others. This morning, the […]

Description: Pfizer (PFE) has beat out Novo Nordisk (NVO) in the bidding war for obesity medicine company Metsera (MTSR). BMO Capital Markets managing director of biopharma equity research, Evan Seigerman, discusses why he thinks the acquisition worked out in the best way for all parties. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.View on euronews

Description: The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants. The S&P 500 is packed with the biggest and the best companies, celebrated for the price swings, cash flow, and high upside potential. The index is massive and is often associated ... 5 Highest Yielding Dividend Stocks in the S&P 500

Description: Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Description: The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Defic

Description: The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and advocacy have spurred global initiatives for better diagnosis, research funding, and equitable access, addressing unmet needs and fostering partnerships. Sickle Cell Disease Treatment Market Sickle Cell Disease Treatment Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Sickle Cell Disease Treatmen

Description: Pfizer Inc. ( NYSE:PFE ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...

Description: For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief. For Eli Lilly’s   David Ricks and Novo Nordisk’s   Mike Doustdar, who paid their own visit to the White House last week, the calculus is different.

Description: The global vaccines market is projected to grow from USD 50.46 billion in 2025 to USD 63.66 billion by 2030, achieving a CAGR of 4.8%. Key drivers include high rates of infectious diseases, technological innovations, and robust government support. The pneumococcal and multivalent vaccine segments dominate due to rising pneumococcal infections and demand for comprehensive immunization, respectively. The Asia Pacific region is the fastest-growing market, driven by increased public health initiativ

Description: Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Description: Pfizer not only beat expectations last quarter, but also boosted its guidance.

Description: Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera

Description: Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth in non-COVID products and disciplined cost management as key drivers of performance. CEO Albert Bourla emphasized the company’s ability to deliver adjusted earnings above expectations, noting, “Our business is performing well, and we are raising the range of our adjusted diluted EPS guidance for full year 2025.” The quarter saw operational declines in legacy COVID-19 prod

Description: Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.

Description: Gain insight on Pfizer’s purchase of Metsera, Roche’s fenebrutinib results, and more in the latest Market Talks covering the health care sector.

Description: ↗️ TSMC (TSM, TW:2330): The contract chip maker's sales rose last month at the slowest pace since February 2024, but remained in double-digits. Its American depositary receipts were up 3.1%, part of a broader rebound in technology stocks.

Description: Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.

Description: After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s likely to continue to pursue other deals. Novo Nordisk’s near-term focus is to launch a pill form of Wegovy, the popular weight-loss drug it first launched in 2021 as a weekly injectable. Novo Nordisk has applied for Food and Drug Administration approval, and expects a decision by year end.

Description: Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He

Description: Health care stocks rose Monday afternoon with the NYSE Health Care Index and the Health Care Select

Description: Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that evening, according to people familiar with the matter, that the board of Metsera Inc., a three-year-old biotech startup developing a new generation of weight-loss drugs, had voted unanimously to accept Pfizer’s takeover offer of as much as $10 billion. It was the climax of a Wall Street duel that had pitted Pfizer against the Danish pharmaceutical giant Novo Nordisk A/S – and a deal that is poised to set the global drug industry’s pecking order for years to come.

Description: The win gives Pfizer a long-awaited foothold in the fast-growing obesity drug market.

Description: The Nasdaq Composite and S&P 500 were up in late-morning trading Monday, while the Dow Jones Industr

Description: Novo Nordisk Shares Pop After Stepping Back From Metsera Chase

Description: Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

Description: Metsera Plunges After Pfizer Secures Revised $86-Per-Share Merger Deal

Description: Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Description: On September 22, Pfizer announced a deal to acquire the shares of promising weight-loss drug start-up Metsera for $5.5bn. On Friday night Metsera...

Description: The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.

Description: <body><p>STORY: Shares in Novo Nordisk rose on Monday (November 10).</p><p>Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.</p><p>Market watchers saw its offer as too complex.</p><p>The Danish drugmaker has also come under more pressure over governance.</p><p>That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.</p><p>Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.</p><p>It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.</p><p>Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.</p><p>The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.</p><p>Metsera cited the antitrust concerns in rejecting Novo's bid.</p><p>The Danish drugmaker confirmed Saturday it would withdraw from the race.</p><p>Novo's shares were up 2.6% by Monday afternoon.</p><p>The stock has lost more than 70% of its value since June last year.</p></body>

Description: Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Pfizer (PFE) outbidding Novo Nordisk (NVO) in its acquisition of Metsera (MTSR), monday.com (MNDY) shares diving nearly 20% in Monday's premarket after falling short of revenue forecast estimates, and Instacart (CART) — which operates as Maplebear, Inc. — beating its third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: US equity futures were up ahead of Monday's opening bell as traders monitored a potential breakthrou

Description: Is your portfolio truly prepared for year-end and 2026?

Description: Skepticism around sky-high tech valuations and a continued dearth of economic data set up the week for investors.

Description: Haleon plc (NYSE:HLN) is one of the stocks Jim Cramer recently discussed. Cramer highlighted the stock’s struggles, as he commented: “With Kimberly-Clark shelling out nearly $49 billion to buy Kenvue, which was originally J&J’s over-the-counter medicine business, I think it’s time to check in with Haleon, the former consumer business of GlaxoSmithKline and Pfizer… Oh, […]

Description: U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy. Metsera, based in New York, has no products on the market, but it is developing oral and injectable treatments. The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity.

Description: There's no need to break the bank to get your hands on excellent dividend payers.

Description: The founders of Metsera had a battle to buy their company. It’s their second time striking deal gold.

Description: <body><p>STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.</p><p>It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. </p><p>Metsera accepted a sweetened offer from Pfizer late Friday (November 7). </p><p>It cited U.S. antitrust risks in Novo's bid that it had previously called superior. </p><p>Novo said in a statement that it believed its offer structure was "compliant with antitrust laws."</p><p>Metsera’s drugs are projected to reach $5 billion in peak sales.</p><p>And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. </p><p>It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.</p><p>The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…</p><p>And that it would "continue to assess opportunities for business development and acquisitions”.</p><p>Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.</p></body>

Description: Pfizer has agreed to buy the weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting Novo Nordisk following a heated bidding war. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday. In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.

Description: The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.

Description: We recently published 10 Stocks on Fire Amid Market Chaos. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera soared to a new all-time high on Thursday as buying appetite was bolstered by an intensifying billion-dollar bidding war from two pharmaceutical giants. At intra-day trading, Metsera, Inc. (NASDAQ:MTSR) climbed to a new […]

Description: Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo...

Description: Pfizer has agreed to buy the weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting Novo Nordisk following a heated bidding war. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday. In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.

Description: Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash.

Description: China’s commitment to innovation poses a long-term threat to U.S. companies. What it needs now is for its citizens to spend more.

Description: Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry.New York, NY, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant governmen

Description: Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

Description: Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?

Description: We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE) reported its third-quarter earnings report yesterday. The results were a solid bunch of numbers that saw the firm post $16.65 billion in revenue and $0.87 in adjusted […]

Description: Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.

Description: Ever wondered if Pfizer is a hidden gem or just treading water in today’s market? Let’s jump in and get to the bottom of whether the stock is truly worth your attention right now. Pfizer’s share price ticked up 2.3% this week, but has still slipped 5.4% in the last month and is down 6.6% year to date, with a modest 1.4% slide over the last year. Market watchers have been parsing several big headlines recently, including the company’s status as a leader in transformational therapies and some...

Description: Elon Musk's targets in order to hit his $1 trillion pay package are aggressive according to Tesla's (TSLA) board. Chris Rossbach from J.Stern agrees. This week concerns over an AI bubble have grown and shares of Nvidia (NVDA), Palantir (PLTR) and AMD (AMD) have faltered. The battle to buy Metsera (MTSR) is intensifying as both Novo Nordisk (NVO, NOVO-B.CO) and Pfizer (PFE) make bids for the obesity drug developer this week.

Description: Pharma rivals fight for control of next-generation obesity drug maker

Description: Factors like healthcare access, urbanization, and innovation, particularly in the U.S., France, and China, propel market expansion. Key players such as Pfizer, Bayer, and GlaxoSmithKline are fostering advancements in PMS therapies. Premenstrual Syndrome Treatment Market Premenstrual Syndrome Treatment Market Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, Countries and Company Analysis 2025-2033" has been adde

Description: The founders of Metsera have a battle to buy their company. It would be their second time striking deal gold.

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a […]

Description: US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host Josh Lipton to take a closer look at what the deals mean for the companies. Breen also discusses Pfizer's (PFE) legal case to block Novo Nordisk's (NVO) Metsera (MTSR) acquisition. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.

Description: Eli Lilly (LLY) and Novo Nordisk (NVO) will reduce US prices for their popular weight-loss and diabe

Description: Novo Nordisk’s chief executive challenged Pfizer to increase its bid for obesity start-up Metsera, as the Denmark-based drugmaker again bested...

Description: ↗️ Marvell (MRVL): Japan's SoftBank (JP:9984) explored a potential takeover of the U.S. semiconductor maker, intending to merge it with Arm (ARM), Bloomberg reported. Marvell shares closed up about 0.

Description: Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.

Description: The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.

Description: Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramer’s radar. Cramer noted that the company could not perform as its entire industry is going through a tough time. He remarked: “…We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are historically […]

Description: Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: “Yeah, I know, and I’ve watched that, and I don’t, I think […]

Description: Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Description: You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating cash income from their portfolio, but if you handle the income well, you can generate a higher total return through dividend reinvestment while boosting the long-term capital appreciation potential. Pfizer (NYSE: PFE), ... No Brainer Dividend Stocks To Buy Now

Description: On November 5, 2025, Novo Nordisk reported lower full-year sales and profit guidance following third-quarter results amid slowing growth in its obesity and diabetes businesses, while presenting new clinical data showing Wegovy’s benefits in lowering obesity-related health risks and pursuing regulatory approval for a higher dose. This period also saw heated legal battles with Pfizer over the acquisition of obesity biotech Metsera and the announcement of significant restructuring efforts,...

Description: MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

Description: AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.

Description: The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.

Description: Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on Thursday. Sales of Moderna’s respiratory syncytial virus, or RSV, vaccine remain negligible, and the company had a net loss of $200 million for the quarter. The quarter’s revenue of $1 billion beat the FactSet consensus estimate of $900 million.

Description: Here are some of the stocks that are on the move on Thursday, Nov. 6. Penn Entertainment (PENN) and Disney's (DIS) ESPN are ending their sports-betting agreement early. ESPN announced DraftKings (DKNG) as a new partner. There are new developments in the Pfizer (PFE) and Novo Nordisk (NVO) bidding war for Metsera (MTSR). A federal judge has agreed to dismiss a criminal case tied to two Boeing (BA) 737 MAX crashes. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer:

Description: Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.

Description: NEW YORK, November 05, 2025--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Novo Nordisk stock reversed higher Wednesday, though the Wegovy and Ozempic maker cut its sales outlook for the third time this year.

Description: Moderna reports earnings early Thursday as investors wonder whether the biotech will run through its pandemic-era windfall before it stops losing money. The vaccine company had accumulated nearly $20 billion in cash by early 2022, thanks to the record-smashing sales of its Covid-19 shot, but has been losing billions of dollars a year since 2023. Management has said Moderna will have $6 billion left at the end of this year, will stop losing money in 2028, and won’t need to raise any new cash to bridge the gap.

Description: Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements for a premerger review.

Description: Arvinas Inc (ARVN) showcases promising clinical progress and strategic partnerships, despite facing revenue declines and operational downsizing.

Description: The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Description: Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma giant.

Description: The CNS Summit Digital Innovation Index, created in partnership with IDEA Pharma, a division of SAI Med Partners, was unveiled during the CNS Summit annual meeting on November 4. The Index continues to assess and rank biopharma companies' progress in digital innovation across three key dimensions:

Description: – Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a thir

Description: Both companies have upped their bids, but Novo Nordisk comes armed with an extra $1.9bn.

Description: AMD beats expectations, Mamdani wins NYC mayoral election, Bitcoin briefly dips below $100,000, and more news to start your day.

Description: Competition and pricing weigh on the maker of Ozempic and Wegovy

Description: We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Tuesday. Metsera rallied to a new all-time high on Tuesday after pharmaceutical giant Novo Nordisk heated up efforts to snatch the company from Pfizer Inc. for an upsized $10 billion acquisition offer. In intra-day trading, […]

Description: Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer's bid of $8 billion.

Description: Three factors took Viking's shares higher in the month.

Description: The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMark

Description: Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.

Description: A new regulatory filing shows that billionaire investor Michael Burry's hedge fund Scion Asset Management purchased five million put options on Palantir Technologies, Inc. (NASDAQ:PLTR) and one million put options on NVIDIA Corp. (NASDAQ:NVDA), among ...

Description: Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7%. Year-over-year, EPS growth soared 133.3%, marking a sharp reversal from the company’s five-year average decline of 13.2% per year, even as a significant one-off loss of $4.7 billion weighed on the latest results. Looking ahead, investors are weighing the company’s stronger margins and attractive valuation multiples against forecasts for a 3.2% annual decline in...

Description: Jared Holz, Mizuho Securities Healthcare Equity Strategist, says he wouldn't be surprised to see one more bid from Pfizer. He tells Katie Greifeld and Matt Miller on "The Close" that Pfizer made it clear without saying so directly that its latest attempt may not be the final one.

Description: ↘️ Palantir (PLTR): Shares closed down 8%. The data-analytics company reported another quarter of record revenue but having more than doubled so far in 2025, the stock was priced for perfection. ↘️ Sarepta Therapeutics (SRPT): Shares tumbled 34% after the biotech company said results from a yearslong trial of two therapies for a rare muscle-wasting illness fell short of statistical significance.

Description: The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Description: Shares in data analytics software developer Palantir tumble even as the company tops analysts' earnings estimates.

Description: The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more heated.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Pfizer stock dipped early Tuesday despite hiking its 2025 profit guidance, as third-quarter sales and earnings both toppled year over year.

Description: Despite a drop in COVID product demand, Pfizer Inc (PFE) surpasses EPS expectations and advances key strategic initiatives.

Description: Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked $8.1 billion proposal.

Description: Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index and the Health Ca

Description: On November 4, 2025, Pfizer reported third-quarter earnings showing a year-over-year decline in revenue to US$16.65 billion and net income to US$3.54 billion, while reaffirming full-year revenue guidance between US$61.0 billion and US$64.0 billion. The company's results reflect ongoing operational pressures, challenges related to COVID-19 product demand, and the impact of legal disputes over its bid for obesity drug developer Metsera. We'll explore how Pfizer's ongoing legal battle over the...

Description: The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential milestone payments.

Description: Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Description: Pfizer shares were lower on Tuesday despite third-quarter financial results that came in ahead of expectations. Adjusted diluted earnings came in at $0.87 per share, well ahead of the $0.63 per share consensus estimate. The stronger-than-expected revenue came from older products, while cost cuts and lower-than-expected tax liabilities helped the bottom line.

Description: European stock markets closed mixed in Tuesday trading as the Stoxx Europe was down 0.30%, Germany's

Description: All three major US stock indexes were down in late-morning trading Tuesday, as concerns mount over v

Description: “Sometimes, we see bubbles,” Burry said in a recent X post. “Sometimes, there is something to do about it. Sometimes, the only winning move is not to play.”

Description: Albert Bourla: The past few months have been pivotal for Pfizer Inc. We are really excited about our future and confident that we are in a strong position to continue delivering value for patients and our shareholders. What I can say, is that our belief in the promise of the Pfizer Inc. and MedCera combination is strong, and unwavering, We are confident it will create substantial value for shareholders and advance innovation to bring important medicines to patients in the high-growth therapeutic area of obesity.

Description: Yahoo Finance Senior Reporter Allie Canal outlines what investors are watching on Tuesday, Nov. 4. Pfizer (PFE), Uber (UBER), Spotify (SPOT), and BP (BP) are among the companies releasing earnings ahead of the opening bell. AMD (AMD), Pinterest (PINS), Rivian (RIVN), and Cava (CAVA) will continue the wave of earnings after the closing bell. ADP (ADP) is set to release a new weekly labor market report amid the ongoing government shutdown. Watch the video above to learn more about the stories that the market is watching. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The Nasdaq Composite and the S&P 500 advanced in an overall mixed session on Monday, with Amazon.com

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.

Description: The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around the company.

Description: US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)

Description: Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the

Description: These two leading drugmakers are fighting over a promising GLP-1 candidate.

Description: Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech...

Description: The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.

Description: Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.

Description: The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with […]

Description: Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:

Description: (Updates to add comment from Novo Nordisk in the sixth paragraph.) Pfizer (PFE) said late Friday

Description: There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a $9.7 billion deal with Microsoft (MSFT). Pfizer (PFE) is suing to block Novo Nordisk's (NVO) bid for obesity startup Metsera (MTSR). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: NEW YORK, November 03, 2025--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.

Description: Pfizer called Novo Nordisk’s last-minute bid to acquire Metsera “reckless and unprecedented”.

Description: These healthcare stocks are making strides in very important ways.

Description: The benchmark US stock measures were tracking in the green before the opening bell Monday as traders

Description: Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Description: Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump’s tariffs, and ADP will release October employment data.

Description: Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.

Description: Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Description: Pfizer stock has dropped 50% over the past three years.

Description: The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

Description: It is hard to get excited after looking at Pfizer's (NYSE:PFE) recent performance, when its stock has declined 9.4...

Description: The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.

Description: Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:

Description: Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday.

Description: Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused company.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: NEW YORK, October 31, 2025--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreement between Pfizer and Metsera.

Description: NEW YORK, October 31, 2025--Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).

Description: Pfizer (PFE) could leverage its White House connections to counter Novo Nordisk's (NVO) bid for obes

Description: Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.

Description: Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

Description: AbbVie stock dropped Friday after the biopharmaceutical company reported mixed results across its drug portfolios in the third quarter. Shares declined 4.7% to $217.50, putting AbbVie on pace for its lowest same-day percentage decrease since May 14, according to Dow Jones Market Data. Pharma peers traded mixed: Johnson & Johnson fell slightly while Pfizer gained 0.7%.

Description: <body><p>STORY: :: Novo Nordisk </p><p>Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.</p><p>That’s according to a LinkedIn post by CEO Mike Doustdar Friday. </p><p>As jobs were slashed globally, he added that the pace of informing people varied according to local laws. </p><p>It’s part of Doustdar’s restructuring drive which he launched last month. </p><p>And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.</p><p>The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights.  </p><p>:: Pfizer </p><p>The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. </p><p>The drugmakers are vying for access to its once-monthly GLP-1 injectable.</p><p>Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. </p><p>Metsera is one of several companies developing experimental weight-loss drugs.</p><p>The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.</p><p>That was over concerns it was not moving fast enough in the obesity market.</p></body>

Description: We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. […]

Description: U.S. drugmaker may leverage political ties as takeover battle intensifies

Description: Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Description: Earnings preview of key companies reporting in the coming week and what to look out for.

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently talked about. During the lightning round, when a caller asked about the stock, Cramer commented: “I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it. But […]

Description: Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.